Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.7%

3 terminated out of 45 trials

Success Rate

88.0%

+1.5% vs benchmark

Late-Stage Pipeline

11%

5 trials in Phase 3/4

Results Transparency

32%

7 of 22 completed with results

Key Signals

7 with results88% success

Data Visualizations

Phase Distribution

30Total
Not Applicable (11)
P 1 (7)
P 2 (7)
P 3 (4)
P 4 (1)

Trial Status

Completed22
Recruiting8
Unknown4
Withdrawn4
Terminated3
Suspended1

Trial Success Rate

88.0%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (45)

Showing 20 of 20 trials
NCT07012395Phase 2Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07541261Not Yet RecruitingPrimary

A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia

NCT07196410Phase 1RecruitingPrimary

KAN-004 for Immune-Related Diarrhea or Colitis

NCT04038619Phase 1RecruitingPrimary

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

NCT03819296Phase 1Recruiting

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

NCT05726396Phase 2Withdrawn

A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis

NCT05333978Not ApplicableSuspended

Optoacoustic Detection of Inflammation Using MSOT Device

NCT04407247Phase 1Active Not RecruitingPrimary

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

NCT06206707Not ApplicableRecruiting

FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis

NCT06424769Not ApplicableEnrolling By Invitation

Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management

NCT07047339Phase 2RecruitingPrimary

Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis

NCT02768038WithdrawnPrimary

Intestinal Microbiome and Chronic Inflammatory Bowel Disease

NCT01369355Phase 3Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

NCT02600143Completed

Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.

NCT02647866Phase 2Completed

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

NCT06074874CompletedPrimary

Intestinal Biomarker Analysis After ECP for ICI Colitis

NCT06223347RecruitingPrimary

Improved and Simplified Staining Technique for Dysplasia Detection in Colitis

NCT03378167Phase 1Completed

PediCRaFT: Pediatric Crohn's Disease Fecal Transplant Trial

NCT00272818Completed

Study to Identify Non-Invasive Markers of Gastrointestinal Allergy

NCT05947669Phase 3RecruitingPrimary

Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis

Scroll to load more

Research Network

Activity Timeline